Astellas Doses First Patient in Phase 3 Study of ASP2138, a Subcutaneous Bispecific T-Cell Engager for CLDN18.2-Positive Gastric Cancer
核心洞察
Astellas has dosed the first patient in a Phase 3 trial of ASP2138, a subcutaneously administered bispecific antibody targeting CLDN18.2 (搜索) and CD3 (搜索)-positive T cells, in first-line advanced gastric/GEJ cancer.
The randomized, double-blind, placebo-controlled study will enroll 570 participants and evaluates ASP2138 plus chemotherapy and pembrolizumab against placebo plus chemotherapy with or without pembrolizumab.
Co-primary endpoints are overall survival and progression-free survival, with the trial aiming to break the 6-to-7-month median progression-free survival ceiling of current standard-of-care regimens.
Astellas Pharma Inc. has dosed the first patient in a Phase 3 study evaluating ASP2138, an investigational subcutaneously administered bispecific antibody, as first-line treatment in adults with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are Claudin 18.2 (CLDN18.2 (搜索))-positive and HER2-negative. The announcement, made on August 24, 2026, marks an important milestone in Astellas' commitment to advancing CLDN18.2 science through a portfolio of approved treatments and investigational assets.
The move is driven by a persistent clinical ceiling: despite recent advances, many people with advanced gastric and GEJ cancers continue to face poor outcomes, with median progression-free survival of 6 to 7 months with non-CLDN18.2 (搜索)-directed current standard of care. That stubborn number is precisely why Astellas is advancing a mechanistically distinct weapon into Phase 3.
Mechanism of Action
ASP2138 is an investigational subcutaneously administered bispecific antibody designed to bind to CLDN18.2 (搜索), a protein expressed on certain tumor cells, and CD3 (搜索)-positive T cells, a type of white blood cell with the ability to kill cancer cells. By binding to both targets, ASP2138 is intended to bring these T cells closer to CLDN18.2-expressing tumor cells and activate their anti-tumor response.
This mechanism distinguishes ASP2138 from zolbetuximab (Vyloy), Astellas' own approved CLDN18.2 (搜索)-targeting antibody, which has already demonstrated first-line benefit in the same biomarker-selected population. Whereas zolbetuximab relies on antibody-dependent cellular cytotoxicity, ASP2138 engages T cells directly, redirecting immune killing machinery to the tumor surface. Astellas is effectively running a franchise strategy: anchoring the target, then layering mechanistic diversity on top of it.
Study Design
The Phase 3, randomized, double-blind, placebo-controlled study is designed to evaluate the efficacy and safety of ASP2138 plus chemotherapy (CAPOX or mFOLFOX6) with pembrolizumab versus placebo plus chemotherapy with or without pembrolizumab as first-line treatment in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma whose tumors are CLDN18.2 (搜索)-positive and HER2-negative.
The co-primary endpoints are overall survival and progression-free survival. The study plans to enroll 570 participants across multiple countries. The comparator arm is a flexible control that should accommodate real-world prescribing patterns across multiple countries. The trial layers ASP2138 on top of a combination already validated by the KEYNOTE-859 data that underpinned pembrolizumab's approval in this setting.
Subcutaneous Delivery and Clinical Implications
The subcutaneous delivery route deserves attention beyond convenience. Bispecific T-cell engagers in oncology have historically been administered intravenously, with cytokine release syndrome management complicating outpatient use. A subcutaneous format, if the safety profile from earlier-phase work holds at scale, changes the administration calculus for community oncology settings where gastric cancer (搜索) patients are frequently treated. That distinction will matter to investigators and payers evaluating the full cost of care, not just efficacy deltas.
Strategic Context
Tadaaki Taniguchi, M.D., Ph.D., Chief Research and Development Officer at Astellas, said: "The first patient dosed in this Phase 3 study is an important milestone for ASP2138 and for our broader work in CLDN18.2 (搜索). By advancing multiple scientific approaches, we are building the evidence needed to better understand how CLDN18.2-targeted innovation may help address patient needs."
As Astellas' lead program within its Immuno-Oncology Primary Focus, the ASP2138 Phase 3 study supports the company's execution of its Corporate Strategic Plan, including its ambition to initiate five or more Phase 3 or pivotal studies by fiscal year 2027. ASP2138 is therefore carrying both scientific and portfolio-level weight simultaneously.
The number to track from here is the progression-free survival readout: if ASP2138 plus pembrolizumab plus chemotherapy breaks meaningfully past the six-to-seven-month floor established by pembrolizumab-based regimens alone, the T-cell engager mechanism earns its franchise credentials. If it merely matches, the differentiation story collapses. The safety and efficacy of ASP2138 have not been established for the uses being considered, and there is no guarantee that ASP2138 will receive regulatory approval and become commercially available for the uses being investigated.